2017 Aug 30
Impact of the FDA Approval of CTL019 in ALL
Gail J. Roboz, M.D., discusses the impact of the FDA approval of tisagenlecleucel (CTL019; Kymriah) in select pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). Read more